Clinical trial · Observational
Study of Cancers After Solid Organs Transplants
Epidemiological, Immunological, Pathological and Pharmacogenetic Study of Cancers Occuring After Solid Organs Transplants
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
About 1500 solid organs transplants are performed each year in the Paris agglomeration. Cancer risk in the transplanted is about three times higher than in a population of the same age without any organ transplant. Thus cancer is an important problem for organ transplant. These cancers can be related to many factors : * Post-transplant cancers are due in part to the non specific immunosuppression, which leads to oncogenic viruses replication, and then produces virus inducted cancers (as lymphoma due to EBV virus). * Post-transplant cancers can also be due to the carcinogenic factors of the immunosuppressive drugs (as cyclosporine or tacrolimus, which can cause the appearance of metastases). However, a new type of immunosuppressive drugs (mTOR inhibitors) appear to have anti-cancer properties. * Post-transplant cancers which are not virus-inducted can be relied to genetic factors of the transplanted patient and/or the transplant donor. There are 4 axes in this study : * Axis 1 : Epidemiological, clinical and biological study of the incident cancers in transplanted patients. * Axis 2 : Qualitative and quantitative immunological study of lymphocyte cells by the transplanted patient (determine their characteristics when a cancer appears). * Axis 3 : Pathological and genetic study of the post-transplant cancer cells (see if the cancer is caused by the donor or the recipient). Creation of a biobank. * Axis 4 : Pharmacogenetic study of the immunosuppressive drugs (determine the impact of patient genetic variability on tolerance and efficiency of the immunosuppressive drugs).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Organ Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Patient-Case
- description
- Transplanted patient with cancer
- label
- Patient-Control
- description
- Transplanted patient without cancer
Primary outcomes (1)
- measure
- Incidence of cancer among transplanted patients.
- timeFrame
- At the day of blood collection
Secondary outcomes (2)
- measure
- Characteristics of the tumors.
- timeFrame
- At the day of blood collection
- measure
- Risk factors of the tumors.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Man or woman after 18 years old * Transplanted with a solid organ (heart, kidney, lung,liver) * Informed Consent Form signed * For the patients-case: Patients who developed a post-transplant cancer * For the patients-control: Patients who didn't develop a post-transplant cancer Exclusion Criteria: * Cancer as transplant indication ( except liver ) * HIV positive
References
Publications (0)
Data not yet available